Cargando…
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
Immunotherapy and immune checkpoint blocking antibodies such as anti-PD-1 are approved and significantly improve the survival of advanced non-small cell lung cancer (NSCLC) patients, but there has been little success in identifying biomarkers capable of separating the responders from non-responders...
Autores principales: | Jafarnejad, Mohammad, Gong, Chang, Gabrielson, Edward, Bartelink, Imke H., Vicini, Paolo, Wang, Bing, Narwal, Rajesh, Roskos, Lorin, Popel, Aleksander S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591205/ https://www.ncbi.nlm.nih.gov/pubmed/31236847 http://dx.doi.org/10.1208/s12248-019-0350-x |
Ejemplares similares
-
A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
por: Milberg, Oleg, et al.
Publicado: (2019) -
A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition
por: Gong, Chang, et al.
Publicado: (2017) -
In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
por: Wang, Hanwen, et al.
Publicado: (2019) -
Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors
por: Gong, Chang, et al.
Publicado: (2019) -
Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
por: Baverel, Paul, et al.
Publicado: (2019)